Best Hospitals for Pancreas Transplant in Dubai, UAE

The pancreas serves a dual physiological role: its exocrine component produces digestive enzymes essential for nutrient absorption, while its endocrine islet cells—specifically the beta cells of the Islets of Langerhans—secrete insulin and glucagon to maintain glycemic homeostasis. In Type 1 diabetes mellitus, autoimmune destruction of beta cells leads to absolute insulin deficiency, forcing patients into lifelong exogenous insulin dependency with attendant risks of hypoglycemic unawareness, diabetic nephropathy, retinopathy, neuropathy, and cardiovascular disease. In advanced cases of chronic pancreatitis or post-total pancreatectomy states, both exocrine and endocrine function are lost simultaneously.

• IDEAL CANDIDATES:
• Type 1 diabetes mellitus with absolute insulin deficiency confirmed by low fasting C-peptide levels (<0.3 ng/mL)
• Brittle (labile) diabetes with recurrent, severe hypoglycemia or hypoglycemic unawareness unresponsive to optimal medical management including continuous glucose monitors and closed-loop insulin pump systems
• Diabetic nephropathy with eGFR <20 mL/min/1.73m² (SPK) or functioning renal allograft (PAK)
• Type 1 diabetes without renal failure but with life-threatening metabolic instability (PTA)
• +21 more

SIMULTANEOUS PANCREAS-KIDNEY (SPK) TRANSPLANT — STANDARD APPROACH: The SPK procedure is performed under general anesthesia via a midline or bilateral lower-quadrant laparotomy. The pancreatic allograft (procured with the duodenal segment intact) is implanted in the right iliac fossa with arterial reconstruction using a donor Y-graft (iliac artery bifurcation) anastomosed end-to-side to the recipient right common or external iliac artery. Venous drainage is achieved via end-to-side anastomosis to the right common iliac vein (systemic drainage) or, at select centers using the portal-enteric drainage technique, to the superior mesenteric vein for more physiological insulin delivery directly into the portal circulation. Exocrine secretions are drained via a duodeno-jejunostomy (enteric drainage)—now the preferred technique globally—avoiding the metabolic complications of the older bladder-drainage method. The renal allograft is implanted separately in the left iliac fossa using standard techniques. Total operative time is typically 4–6 hours.

PANCREAS AFTER KIDNEY (PAK) AND PANCREAS TRANSPLANT ALONE (PTA): These are technically similar to the SPK pancreas implantation but performed as single-organ procedures. PTA candidates must meet stringent metabolic criteria, and careful risk-benefit analysis is essential given the immunosuppression burden without the concomitant renal benefit.

MINIMALLY INVASIVE AND ROBOTIC-ASSISTED APPROACHES: A small number of high-volume academic centers have begun performing robotic-assisted pancreas transplantation using the da Vinci Xi surgical system. This technique involves 4–5 port placements and uses intracorporeal vascular anastomosis. Reported advantages include reduced wound complications (particularly in obese patients), lower incidence of incisional hernia, and shorter hospital stay. While not yet the global standard, robotic pancreas transplantation represents the most advanced frontier of the procedure and is available at select centers partnered with GAF Healthcare.

ISOLATED ISLET CELL TRANSPLANTATION (EDMONTON PROTOCOL): For selected PTA candidates—particularly those with prohibitive surgical risk—intraportal infusion of purified islet cells (700,000–1,000,000 islet equivalents) from one or two donors can restore partial or complete insulin independence. The Edmonton Protocol, refined with anti-inflammatory induction (etanercept, exenatide) and steroid-free immunosuppression, achieves insulin independence in approximately 50–60% of patients at 5 years. Islet transplantation is performed as a minimally invasive percutaneous transhepatic procedure under fluoroscopic guidance and does not require general anesthesia or major surgery. However, it requires an approved islet processing facility and is offered at specialized centers.

PHASE 1 — REMOTE EVALUATION (Weeks 1–3 before travel): Patients submit medical records, recent labs, imaging, and cardiac evaluation results to the GAF Healthcare clinical coordination team. A senior transplant nephrologist and pancreatic transplant surgeon review the case remotely. Virtual consultation is scheduled to confirm candidacy, discuss procedure type (SPK/PAK/PTA), review waitlist logistics (deceased donor) or living-related evaluation, and issue a detailed cost estimate and preliminary treatment plan.

PHASE 2 — ARRIVAL AND PRE-TRANSPLANT WORKUP (Days 1–7 in country): Upon arrival, the patient undergoes a structured inpatient or outpatient pre-transplant evaluation: repeat HLA crossmatch with the identified deceased donor (if transplant is imminent), repeat ECHO, CT angiography review, infectious serology confirmation, and anesthesia fitness assessment. Immunosuppression induction medications are initiated. For deceased-donor transplants, patients may be placed on an active waitlist at the center and must remain in-country. Living-donor pancreas transplantation (rare; partial graft from living donor) is evaluated separately.

PHASE 3 — SURGERY DAY (Day 0): On receipt of a suitable donor organ (cold ischemia time <12 hours is prioritized), the patient proceeds to the operating theater. General anesthesia is induced. The surgical team performs vascular and enteric anastomoses as described above. Intraoperative graft perfusion is confirmed by Doppler ultrasound on the table. Intraoperative blood glucose normalization—typically within 1–2 hours of pancreatic reperfusion—confirms immediate graft function. Operative duration: 4–6 hours (SPK: 5–8 hours).